Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Flora Smith

Family Medicine Saint Clair Shores, MI Nurse Practitioner

NPI 1710455845 CMS profile 5692111

25200 Little Mack Ave, Saint Clair Shores, MI 48081

Open in the dashboard

General payments

$7,579

315 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Flora Smith of Saint Clair Shores, MI is reported in the CMS Open Payments database as having received $7,579 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,654 118
2024 General $2,011 75
2023 General $1,116 51
2022 General $1,297 50
2021 General $501 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Flora Smith
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Flora Smith were reported at $2,654. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Flora Smith Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $501 $137 $35–$551 $132
2022 $1,297 $137 $37–$512 $149
2023 $1,116 $149 $42–$545 $160
2024 $2,011 $156 $44–$560 $164
2025 $2,654 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,139 84 payments
  2. Genzyme Corporation $810 31 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $611 22 payments
  4. GlaxoSmithKline, LLC. $488 26 payments
  5. Regeneron Healthcare Solutions, Inc. $415 15 payments
  6. AbbVie, Inc. $399 8 payments
  7. Amgen Inc. $385 25 payments
  8. CSL Behring $362 16 payments
  9. Pfizer Inc. $258 13 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $247 11 payments
  11. Other $1,466 64 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,379 313 payments
  2. Education $199 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,189 45 payments
  2. TEZSPIRE Respiratory $853 25 payments
  3. FASENRA $495 21 payments
  4. AIRSUPRA $392 16 payments
  5. TEZSPIRE Inflammation $385 25 payments
  6. DUPIXENT Inflammation And Immunology $304 10 payments
  7. Haegarda $262 9 payments
  8. RINVOQ $239 5 payments
  9. CUVITRU $232 8 payments
  10. NUCALA $231 15 payments
  11. Other $3,763 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

896

Median for Family Practice: 1,826

Drug cost

$165,717

Median for Family Practice: $120,094

Branded share of claims

36.5%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 13 $48,914
Breo Ellipta Fluticasone/Vilanterol Brand 67 $28,366
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $26,154
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 32 $22,038
Spiriva Respimat Tiotropium Bromide Brand 24 $12,289
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 18 $4,133
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 21 $3,929
Epinephrine Generic 15 $3,623
Azelastine Hcl Generic 85 $3,163
Wixela Inhub Fluticasone Propion/Salmeterol Brand 14 $2,818

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $317
  • Amgen Inc. $85
$402 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $248
  • GENZYME CORPORATION $145
$393 13 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $247
$247 — —
Haegarda
  • CSL Behring $118
$118 — —
AYVAKIT
  • Blueprint Medicines Corporation $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record